Succesfuld behandling af KCNJ11-neonatal diabetes uden insulin

Research output: Contribution to journal › Letter › Research › peer-review

Standard

Succesfuld behandling af KCNJ11-neonatal diabetes uden insulin. / Gade-Rasmussen, Birthe; Madsbad, Sten; Svane, Maria Saur; Martinussen, Christoffer; Hansen, Torben.

In: Ugeskrift for Laeger, Vol. 180, No. 46, V08180547, 2018.

Research output: Contribution to journal › Letter › Research › peer-review

Harvard

Gade-Rasmussen, B, Madsbad, S, Svane, MS, Martinussen, C & Hansen, T 2018, 'Succesfuld behandling af KCNJ11-neonatal diabetes uden insulin', Ugeskrift for Laeger, vol. 180, no. 46, V08180547. <http://ugeskriftet.dk/videnskab/succesfuld-behandling-af-kcnj11-neonatal-diabetes-uden-insulin>

APA

Gade-Rasmussen, B., Madsbad, S., Svane, M. S., Martinussen, C., & Hansen, T. (2018). Succesfuld behandling af KCNJ11-neonatal diabetes uden insulin. Ugeskrift for Laeger, 180(46), [V08180547]. http://ugeskriftet.dk/videnskab/succesfuld-behandling-af-kcnj11-neonatal-diabetes-uden-insulin

Vancouver

Gade-Rasmussen B, Madsbad S, Svane MS, Martinussen C, Hansen T. Succesfuld behandling af KCNJ11-neonatal diabetes uden insulin. Ugeskrift for Laeger. 2018;180(46). V08180547.

Author

Gade-Rasmussen, Birthe ; Madsbad, Sten ; Svane, Maria Saur ; Martinussen, Christoffer ; Hansen, Torben. / Succesfuld behandling af KCNJ11-neonatal diabetes uden insulin. In: Ugeskrift for Laeger. 2018 ; Vol. 180, No. 46.

Bibtex

@article{c296441539db4aacb5b36d541686ae1a,
title = "Succesfuld behandling af KCNJ11-neonatal diabetes uden insulin",
abstract = "In this case report a 40-year-old insulin-treated male patient presented with a KCNJ11 R201H mutation, which can cause neonatal diabetes. After initiation of treatment with high doses of the sulfonylurea glibencamide in combination with the glucagon-like peptide 1 receptor agonist liraglutide, insulin treatment of the patient could be terminated. The first nine months after termination of insulin treatment the glycated haemoglobin concentration was 48-54 mmol/mol (i.e. 6.5-7.1%).",
author = "Birthe Gade-Rasmussen and Sten Madsbad and Svane, {Maria Saur} and Christoffer Martinussen and Torben Hansen",
year = "2018",
language = "Dansk",
volume = "180",
journal = "Ugeskrift for Laeger",
issn = "0041-5782",
publisher = "Almindelige Danske Laegeforening",
number = "46",

}

RIS

TY - JOUR

T1 - Succesfuld behandling af KCNJ11-neonatal diabetes uden insulin

AU - Gade-Rasmussen, Birthe

AU - Madsbad, Sten

AU - Svane, Maria Saur

AU - Martinussen, Christoffer

AU - Hansen, Torben

PY - 2018

Y1 - 2018

N2 - In this case report a 40-year-old insulin-treated male patient presented with a KCNJ11 R201H mutation, which can cause neonatal diabetes. After initiation of treatment with high doses of the sulfonylurea glibencamide in combination with the glucagon-like peptide 1 receptor agonist liraglutide, insulin treatment of the patient could be terminated. The first nine months after termination of insulin treatment the glycated haemoglobin concentration was 48-54 mmol/mol (i.e. 6.5-7.1%).

AB - In this case report a 40-year-old insulin-treated male patient presented with a KCNJ11 R201H mutation, which can cause neonatal diabetes. After initiation of treatment with high doses of the sulfonylurea glibencamide in combination with the glucagon-like peptide 1 receptor agonist liraglutide, insulin treatment of the patient could be terminated. The first nine months after termination of insulin treatment the glycated haemoglobin concentration was 48-54 mmol/mol (i.e. 6.5-7.1%).

M3 - Letter

C2 - 30417822

VL - 180

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

SN - 0041-5782

IS - 46

M1 - V08180547

ER -

ID: 219535295